Home » Thought Leadership » Blogs

Blogs

1

Showing 5 of 16 posts
September 22, 2020 | Blogs

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

September 17, 2020 | Blogs

Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations

Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.

July 6, 2020 | Blogs

What’s Next for Alzheimer’s Disease?

Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed

Tumour case study
March 24, 2020 | Blogs

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.

Gene editing case study
March 24, 2020 | Blogs

Genome Editing: An Introduction

A topic that is becoming increasingly popular in the healthcare space is Genome Editing. CBPartners’ Cell and Gene Therapy Center of Excellence team explores the development of these technologies as they present an immense opportunity for the future of the pharmaceutical industry.